MAIA Biotechnology, Inc.
MAIA · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.06 | -0.05 | -0.04 |
| FCF Yield | -35.73% | -84.24% | -35.80% | -8.69% |
| EV / EBITDA | -2.03 | -0.41 | -1.34 | -4.76 |
| Quality | ||||
| ROIC | -267.17% | -767.46% | -185.22% | -84.81% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.68 | 0.66 | 0.77 | 0.33 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -20.15% | -12.14% | -182.71% | -123.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.57 | 0.35 | 0.68 | 1.37 |
| Interest Coverage | -297,491.23 | 0.00 | -2,321.80 | -9.41 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |